ArteraAI vs Valar Labs
Both extract prognostic and predictive signal from routine H and E slides, and both hold grade A clinical evidence, which is rare, so the two diverge almost entirely on regulatory standing and where their evidence lives. If your failure mode is deploying a test a payer will not cover or a guideline panel has not vetted, start with ArteraAI, which holds FDA De Novo authorization, NCCN guideline inclusion, and CMS coverage, the most complete standing in the index. If you need a prognostic in bladder cancer, or a test orderable today as a send out without waiting on device clearance, start with Valar Labs, accepting the laboratory developed test evidentiary bar. Their strongest evidence sits in different cancers, so they compete directly only on prostate.
- The most complete regulatory and guideline standing in the index: FDA De Novo authorization in August 2025, inclusion in the NCCN prostate cancer guidelines as the first and only AI risk stratification tool, and CMS coverage with an established payment rate.
- Predictive, not only prognostic: for NCCN intermediate risk patients it estimates whether adding androgen deprivation therapy to radiation will help, described in the literature as the first predictive biomarker for that decision.
- A model a clinician can audit: locked at a stated version with fully enumerated inputs and published cut points tied to explicit ten year risk thresholds.
- The strongest evidence in a genuinely underserved cancer: multi center validation of its bladder assays in the Journal of Urology and European Urology, outperforming guideline based risk stratification across cohorts exceeding 1,000 patients on four continents, a decision ArteraAI does not address.
- Orderable today with no deployment: specimens are sent to Valar's own CLIA certified and CAP accredited laboratory and results return in days, so there is no platform to install.
- Checkable model supervision: more than 500,000 board certified pathologist annotations behind the platform, with effect sizes published plainly.
Side-by-Side
| Axis | A ArteraAI |
V Valar Labs |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | — | |
| HIPAA and BAA Posture | — | |
| Security Certifications and Trust Center | — | |
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | — | |
| EHR and Interoperability Depth | — | |
| Deployment Model and Data Residency | — | |
| Commercial Transparency | ||
| Setting and Specialty Coverage |
The two diverge most on regulatory route, and it governs adoption. ArteraAI is FDA cleared, guideline listed, and CMS covered; Valar reaches the clinic as a laboratory developed test under enforcement discretion, a lower evidentiary bar than clearance, and its Breakthrough Device Designation for the bladder test is a review pathway commitment, not a clearance. Valar's coverage and reimbursement detail was not located, which for a laboratory developed test directly governs whether it is practically orderable. Neither publishes a security attestation, and Valar's specimen and result data reside with its own laboratory by design, a different risk profile rather than an absent one. ArteraAI's grid is assessed on seven axes rather than the full thirteen, so its security, PHI, and deployment posture were not evaluated.